You are currently viewing a beta version of our website. If you spot anything unusual, kindly let us know.

Preprint
Hypothesis

ACE Inhibitors and AT1R Blockers for COVID-2019: Friends or Foes ?

Altmetrics

Downloads

1784

Views

887

Comments

1

This version is not peer-reviewed

Submitted:

21 April 2020

Posted:

22 April 2020

You are already at the latest version

Alerts
Abstract
Human respiratory beta coronavirus are emerging causes for Public Health Emergencies of International Concern (PHEIC). SARS-CoV2 is circulating worldwide since November 2019. We review here the cardiovascular morbidity and mortality in COVID-19, and data supporting the role for dysregulation of the RAS counterregulatory axis due to binding of SARS-CoV2 S protein to ACE2 receptor. Since this counterregulatory axis provides benefits not only on the cardiovascular front but also in acute lung injury, we speculate on potential use of ACE inhibitors and AT1R blockers in critically ill COVID-19 patients, and report current evidences.
Keywords: 
Subject: Biology and Life Sciences  -   Virology
Copyright: This open access article is published under a Creative Commons CC BY 4.0 license, which permit the free download, distribution, and reuse, provided that the author and preprint are cited in any reuse.
Prerpints.org logo

Preprints.org is a free preprint server supported by MDPI in Basel, Switzerland.

Subscribe

© 2024 MDPI (Basel, Switzerland) unless otherwise stated